Camilla Mattiuzzi
Research Subjects
Research Interests
Camilla Mattiuzzi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe Lippi
Section of Clinical Biochemistry , University of Verona , Verona , Italy
62 shared publications - Brandon Michael Henry
Clinical Laboratory, Division of Nephrology & Hypertension, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
15 shared publications - Fabian Sanchis-Gomar
Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA
9 shared publications - Gianfranco Cervellin
Academy of Emergency Medicine and Care, Pavia, Italy.
3 shared publications - Laura Pighi
Clinical Biochemistry Section, Department of Engineering for Innovation Medicine, University of Verona, 37134 Verona, Italy
3 shared publications - Riccardo Nocini
Unit of Otolaryngology, Head and Neck Department, University of Verona, 37134 Verona, Italy
3 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by PAGEPress Publications in Emergency Care Journal
- Vol. 22 (3)
Epidemiology and temporal trends of carbon monoxide poisoning mortality in the United States, 2018–2024
Dear Editor, Carbon monoxide (CO) poisoning remains a significant cause of preventable morbidity and mortality worldwide.1 As a colorless, odorless, and non-irritating gas typically generated by the incomplete combustion of carbon-containing fuels, CO is especially dangerous because exposure may occur without warning. Common sources include residential heating systems, gas-powered appliances, motor vehicles, and generators, making both accidental and intentional exposures a persistent public health issue.2 The clinical manifestations of poisoning range from mild, nonspecific symptoms, up to severe neurological impairment and death, mostly depending on concentration and duration of exposure.2
- 7 July 2026
- Published by PAGEPress Publications in Emergency Care Journal
- Vol. 22 (3)
Open AccessEpidemiology and temporal trends of carbon monoxide poisoning mortality in the United States, 2018–2024
Dear Editor, Carbon monoxide (CO) poisoning remains a significant cause of preventable morbidity and mortality worldwide.1 As a colorless, odorless, and non-irritating gas typically generated by the incomplete combustion of carbon-containing fuels, CO is especially dangerous because exposure may occur without warning. Common sources include residential heating systems, gas-powered appliances, motor vehicles, and generators, making both accidental and intentional exposures a persistent public health issue.2 The clinical manifestations of poisoning range from mild, nonspecific symptoms, up to severe neurological impairment and death, mostly depending on concentration and duration of exposure.2
- Open Access
- 14 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (4) , 580
Advances in Laboratory Diagnosis
Laboratory medicine is a cornerstone of modern clinical practice, providing essential contributions to screening, diagnosis, prognosis and therapeutic management of human disease
- 14 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (4) , 580
Open AccessAdvances in Laboratory Diagnosis
Laboratory medicine is a cornerstone of modern clinical practice, providing essential contributions to screening, diagnosis, prognosis and therapeutic management of human disease
- Open Access
- 8 October 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (10) , e71368
Critical Response to the Comments on the Critical Issue of Infant and Child Mortality in Afghanistan
- 8 October 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (10) , e71368
Open AccessCritical Response to the Comments on the Critical Issue of Infant and Child Mortality in Afghanistan
- Open Access
- 3 October 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eCE1751
Shifts in COVID-19 mortality throughout pandemic: a five-year analysis of healthcare responses
Dear Editor, The coronavirus disease 2019 (COVID-19) pandemic has unprecedentedly affected the global society, healthcare systems, and economies.() Analyzing the place of death of patients with COVID-19 over the first five years of the pandemic offers valuable insights into shifting healthcare dynamics. Therefore, this study aimed to assess trends in COVID-19-caused patient deaths to better understand how healthcare and social infrastructure adapted to the evolving crisis. […] Shifts in COVID-19 mortality throughout pandemic: a five-year analysis of healthcare responses
- 3 October 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eCE1751
Open AccessShifts in COVID-19 mortality throughout pandemic: a five-year analysis of healthcare responses
Dear Editor, The coronavirus disease 2019 (COVID-19) pandemic has unprecedentedly affected the global society, healthcare systems, and economies.() Analyzing the place of death of patients with COVID-19 over the first five years of the pandemic offers valuable insights into shifting healthcare dynamics. Therefore, this study aimed to assess trends in COVID-19-caused patient deaths to better understand how healthcare and social infrastructure adapted to the evolving crisis. […] Shifts in COVID-19 mortality throughout pandemic: a five-year analysis of healthcare responses
- Open Access
- 11 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7)
Correction: Nocini et al. Improving Nasal Protection for Preventing SARS-CoV-2 Infection. Biomedicines 2022, 10, 2966
In the original publication [...].
- 11 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7)
Open AccessCorrection: Nocini et al. Improving Nasal Protection for Preventing SARS-CoV-2 Infection. Biomedicines 2022, 10, 2966
In the original publication [...].
- Open Access
- 3 July 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1695
A Comparative Evaluation of the Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes
Background: The early detection of type 1 diabetes (T1D) through screening for major islet autoantibodies is receiving increasing attention as a public health strategy, exemplified by the recent implementation of a pilot pediatric screening program in Italy. The transition from research-based screening to large-scale population initiatives needs automated and standardized assays that are capable of processing extensive sample volumes. Hence, this study aimed to evaluate the analytical performance and comparability of a fully automated chemiluminescence immunoassay (CLIA) compared to a conventional enzyme-linked immunosorbent assay (ELISA) for the detection of three classes of major islet antibodies—anti-GAD (GADA), anti-IA-2 (IA-2A), and anti-ZnT8 (ZnT8A). Methods: A total of 104 serum specimens were analyzed for each autoantibody using both ELISA (RSR and Medyzim, DYNES, DSX) and CLIA (MAGLUMI 800). Assay precision and linearity were assessed through intra-assay variability studies and dilution protocols. Methods agreement was evaluated with Passing–Bablok regression, Spearman’s correlation, Bland–Altman analysis, and Cohen’s kappa statistics. Results: The CLIA showed good precision and excellent linearity across clinically relevant concentration ranges of all islet antibodies. Correlation coefficients and categorical agreement between CLIA and ELISA were high (r > 0.96 and Cohen’s kappa >0.8 for all), with ZnT8A exhibiting the highest concordance. However, proportional biases were found, as CLIA systematically underestimated GADA and ZnT8A levels, while overestimated IA-2A compared to the ELISA. Conclusions: The CLIA displayed satisfactory precision and agreement with ELISA for GADA, IA-2A, and ZnT8A detection. Our findings support the use of these automated immunoassays in large-scale population initiatives for diagnosing T1D, but we also highlight the need for further efforts to achieve better inter-assay harmonization.
- 3 July 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1695
Open AccessA Comparative Evaluation of the Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes
Background: The early detection of type 1 diabetes (T1D) through screening for major islet autoantibodies is receiving increasing attention as a public health strategy, exemplified by the recent implementation of a pilot pediatric screening program in Italy. The transition from research-based screening to large-scale population initiatives needs automated and standardized assays that are capable of processing extensive sample volumes. Hence, this study aimed to evaluate the analytical performance and comparability of a fully automated chemiluminescence immunoassay (CLIA) compared to a conventional enzyme-linked immunosorbent assay (ELISA) for the detection of three classes of major islet antibodies—anti-GAD (GADA), anti-IA-2 (IA-2A), and anti-ZnT8 (ZnT8A). Methods: A total of 104 serum specimens were analyzed for each autoantibody using both ELISA (RSR and Medyzim, DYNES, DSX) and CLIA (MAGLUMI 800). Assay precision and linearity were assessed through intra-assay variability studies and dilution protocols. Methods agreement was evaluated with Passing–Bablok regression, Spearman’s correlation, Bland–Altman analysis, and Cohen’s kappa statistics. Results: The CLIA showed good precision and excellent linearity across clinically relevant concentration ranges of all islet antibodies. Correlation coefficients and categorical agreement between CLIA and ELISA were high (r > 0.96 and Cohen’s kappa >0.8 for all), with ZnT8A exhibiting the highest concordance. However, proportional biases were found, as CLIA systematically underestimated GADA and ZnT8A levels, while overestimated IA-2A compared to the ELISA. Conclusions: The CLIA displayed satisfactory precision and agreement with ELISA for GADA, IA-2A, and ZnT8A detection. Our findings support the use of these automated immunoassays in large-scale population initiatives for diagnosing T1D, but we also highlight the need for further efforts to achieve better inter-assay harmonization.
- Open Access
- 25 June 2025
- Published by MDPI AG in Preprints.org
Analyzing COVID-19 Deaths by Weekday: A Four-Year Statistical Review (2020–2023)
Background: Earlier studies suggested that coronavirus disease 2019 (COVID-19) mortality may vary by the day of the week, possibly due to healthcare system workflows or reporting delays. This study aimed to assess whether such day-of-week effects exist in U.S. COVID-19 death data from 2020 to 2023. Methods: We extracted nationwide US COVID-19 mortality data from the CDC WONDER database, grouping deaths by weekday for each year from 2020 to 2023. A one-way ANOVA (Analysis of Variance) and Tukey’s HSD (Honest Significant Difference) test were used to assess differences in daily death counts. Additional comparisons were made between aggregated weekday (Monday–Friday) and weekend (Saturday–Sunday) totals. Results: No statistically significant differences were observed in the number of deaths across individual weekdays in any year analyzed (p= 1.000 for all years combined). Post-hoc testing confirmed that all pairwise comparisons between weekdays were non-significant. Sub-analyses of early (2020–2021) and late (2022–2023) pandemic periods also showed no significant variation (all p-values > 0.05). In the weekday-versus-weekend analysis, average deaths were slightly higher on weekdays during 2020–2021 and marginally higher on weekends during 2022–2023, but none the combined difference failed to reach statistical significance (p=0.969). Conclusions: Official COVID-19 mortality data from 2020 to 2023 in the US show no evidence of a “weekend effect,” indicating that day of the week did not significantly influence reported deaths.
- 25 June 2025
- Published by MDPI AG in Preprints.org
Open AccessAnalyzing COVID-19 Deaths by Weekday: A Four-Year Statistical Review (2020–2023)
Background: Earlier studies suggested that coronavirus disease 2019 (COVID-19) mortality may vary by the day of the week, possibly due to healthcare system workflows or reporting delays. This study aimed to assess whether such day-of-week effects exist in U.S. COVID-19 death data from 2020 to 2023. Methods: We extracted nationwide US COVID-19 mortality data from the CDC WONDER database, grouping deaths by weekday for each year from 2020 to 2023. A one-way ANOVA (Analysis of Variance) and Tukey’s HSD (Honest Significant Difference) test were used to assess differences in daily death counts. Additional comparisons were made between aggregated weekday (Monday–Friday) and weekend (Saturday–Sunday) totals. Results: No statistically significant differences were observed in the number of deaths across individual weekdays in any year analyzed (p= 1.000 for all years combined). Post-hoc testing confirmed that all pairwise comparisons between weekdays were non-significant. Sub-analyses of early (2020–2021) and late (2022–2023) pandemic periods also showed no significant variation (all p-values > 0.05). In the weekday-versus-weekend analysis, average deaths were slightly higher on weekdays during 2020–2021 and marginally higher on weekends during 2022–2023, but none the combined difference failed to reach statistical significance (p=0.969). Conclusions: Official COVID-19 mortality data from 2020 to 2023 in the US show no evidence of a “weekend effect,” indicating that day of the week did not significantly influence reported deaths.
- Open Access
COVID-19 Mortality Trends over the First Five Years of the Pandemic in the US
Background/Objectives: This retrospective observational study investigated coronavirus disease 2019 (COVID-19)-related mortality trends in the US throughout the pandemic. Methods: We performed a retrospective, descriptive analysis between 2020 and 2024 using data from the US National Center for Health Statistics. Results: The total number of COVID-19 deaths rose by 19% from 2020 to 2021, followed by a significant decline in the subsequent years, with an average reduction factor of 0.44. Mortality rates remained higher in males compared to females, with a gender disparity between 52 and 62%. Age-specific crude mortality rates increased with advancing age, with higher mortality observed in older populations. However, crude death rates significantly declined across all ages except for the 1–4 years group, which experienced a 33% increase. The majority of fatalities occurred in medical facilities (63–80%), but this proportion gradually decreased over time, while the percentage of deaths occurring at home nearly doubled from 2020 to 2024 (6% to 11%). Conclusions: The initial mortality peak for COVID-19 was followed by a substantial decline, likely influenced by the widespread availability of vaccines, improvements in clinical management, and the emergence of less virulent variants. The persistent gender and age disparities, alongside the fluctuating distribution of the places of death, offer insights for refining healthcare policies and optimizing resource allocation in this and other future pandemics.
Open AccessCOVID-19 Mortality Trends over the First Five Years of the Pandemic in the US
Background/Objectives: This retrospective observational study investigated coronavirus disease 2019 (COVID-19)-related mortality trends in the US throughout the pandemic. Methods: We performed a retrospective, descriptive analysis between 2020 and 2024 using data from the US National Center for Health Statistics. Results: The total number of COVID-19 deaths rose by 19% from 2020 to 2021, followed by a significant decline in the subsequent years, with an average reduction factor of 0.44. Mortality rates remained higher in males compared to females, with a gender disparity between 52 and 62%. Age-specific crude mortality rates increased with advancing age, with higher mortality observed in older populations. However, crude death rates significantly declined across all ages except for the 1–4 years group, which experienced a 33% increase. The majority of fatalities occurred in medical facilities (63–80%), but this proportion gradually decreased over time, while the percentage of deaths occurring at home nearly doubled from 2020 to 2024 (6% to 11%). Conclusions: The initial mortality peak for COVID-19 was followed by a substantial decline, likely influenced by the widespread availability of vaccines, improvements in clinical management, and the emergence of less virulent variants. The persistent gender and age disparities, alongside the fluctuating distribution of the places of death, offer insights for refining healthcare policies and optimizing resource allocation in this and other future pandemics.
- Open Access
- 27 May 2025
- Published by MDPI AG in Preprints.org
Comparative Evaluation of Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes
Background: Early detection of type 1 diabetes (T1D) through major islet antibodies screening is gaining momentum as public health strategy, with Italy recently implementing a pilot pediatric screening program. The transition from research-based screening to large-scale population initiatives needs automated and standardized assays capable of processing extensive sample volumes. This study was hence aimed at evaluating the analytical performance and comparability of a fully-automated chemiluminescence immunoassay (CLIA) compared to a conventional enzyme-linked immunosorbent assay (ELISA) for detection of three classes of major islet antibodies anti-GAD (GADA), anti-IA-2 (IA-2A) and anti-ZnT8 (ZnT8A). Methods: A total of 104 serum specimens were analyzed for each autoantibody using both ELISA (DYNES, DSX) and CLIA (MAGLUMI 800). Assay precision and linearity were assessed through intra-assay variability studies and dilution protocols. Methods agreement was evaluated with Passing-Bablok regression, Spearman’s correlation, Bland-Altman analysis and Cohen’s kappa statistics. Results: CLIA showed good precision and excellent linearity across clinically relevant concentration ranges of all islet antibodies. Correlation coefficients and categorical agreement between CLIA and ELISA were high (r>0.96 and Cohen’s kappa >0.8 for all), with ZnT8A exhibiting the highest concordance. However, proportional biases were found, as CLIA systematically underestimated GADA and ZnT8A levels, while overestimated IA-2A compared with ELISA. Conclusions: CLIA assays displayed satisfactory precision and agreement with ELISA for GADA, IA-2A and ZnT8A detection. Our findings support the use of these automated immunoassay in large-scale population initiatives for diagnosing TD1, but we also highlight the need for further efforts to achieve better inter-assay harmonization.
- 27 May 2025
- Published by MDPI AG in Preprints.org
Open AccessComparative Evaluation of Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes
Background: Early detection of type 1 diabetes (T1D) through major islet antibodies screening is gaining momentum as public health strategy, with Italy recently implementing a pilot pediatric screening program. The transition from research-based screening to large-scale population initiatives needs automated and standardized assays capable of processing extensive sample volumes. This study was hence aimed at evaluating the analytical performance and comparability of a fully-automated chemiluminescence immunoassay (CLIA) compared to a conventional enzyme-linked immunosorbent assay (ELISA) for detection of three classes of major islet antibodies anti-GAD (GADA), anti-IA-2 (IA-2A) and anti-ZnT8 (ZnT8A). Methods: A total of 104 serum specimens were analyzed for each autoantibody using both ELISA (DYNES, DSX) and CLIA (MAGLUMI 800). Assay precision and linearity were assessed through intra-assay variability studies and dilution protocols. Methods agreement was evaluated with Passing-Bablok regression, Spearman’s correlation, Bland-Altman analysis and Cohen’s kappa statistics. Results: CLIA showed good precision and excellent linearity across clinically relevant concentration ranges of all islet antibodies. Correlation coefficients and categorical agreement between CLIA and ELISA were high (r>0.96 and Cohen’s kappa >0.8 for all), with ZnT8A exhibiting the highest concordance. However, proportional biases were found, as CLIA systematically underestimated GADA and ZnT8A levels, while overestimated IA-2A compared with ELISA. Conclusions: CLIA assays displayed satisfactory precision and agreement with ELISA for GADA, IA-2A and ZnT8A detection. Our findings support the use of these automated immunoassay in large-scale population initiatives for diagnosing TD1, but we also highlight the need for further efforts to achieve better inter-assay harmonization.